Applied DNA Sciences (NASDAQ: APDN) reported Q2 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $905 thousand versus the consensus estimate of $1 million.

Cash and cash equivalents as of March 31, 2017 totaled $4.0 million as compared to $6.7 million at December 31, 2016. The decrease in cash balances is due primarily to cash used in operations.

For earnings history and earnings-related data on Applied DNA Sciences (APDN) click here.